ClinConnect ClinConnect Logo
Search / Trial NCT05013125

ENDO-AID Assisted Tandem Colonoscopy RCT

Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 13, 2021

Trial Information

Current as of May 19, 2025

Completed

Keywords

Computer Aided Polyp Detection Colonoscopy Polyp Detection Colorectal Polyps Colorectal Cancer

ClinConnect Summary

Colorectal cancer is the third common cancer in the world and the commonest cancer in Hong Kong. Most sporadic colorectal cancers arise from benign polyps via adenoma-carcinoma sequence or the serrated polyp-carcinoma sequence. There are reports of unexpectedly high risk of interval carcinomas, as high as up to 9%, raising concerns about the effectiveness of colonoscopy in preventing colorectal cancers. Different techniques have been described to improve the area of mucosa visualised but lesions may still be missed due to failure of identification by the endoscopist.

Computer Aided diagnos...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged 18years or above
  • Referred to endoscopy unit for diagnostic or surveillance colonoscopy
  • Exclusion Criteria:
  • Familial history of Familial adenomatous polyposis / Hereditary non-polyposis colorectal cancer
  • Known history of inflammatory bowel disease
  • Known colitis or suspicion of colitis (inflammatory bowel disease, diverticulitis, infective colitis)
  • Emergency endoscopy of any nature (eg gastrointestinal bleeding, colonic decompression)
  • Previous incomplete colonoscopy (not including insufficient preparation) / difficult colonoscopy
  • Patients referred for a therapeutic procedure or assessment of a known non-resected lesion
  • Patients with known palliative colorectal malignancy
  • Patient with coagulopathy
  • Patient with colostomy
  • Patient with multiple co-morbidities (American Society of Anaesthesiologist \>3)
  • Inability to give informed consent

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Shatin, New Territories, Hong Kong

Patients applied

0 patients applied

Trial Officials

Kaori Futaba

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials